This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Assertio Holdings's Median PS Value or its related term are showing as below:
ASRT'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13 Med: 0.43 Max: 1.2
Current: 0.37
During the past 13 years, the highest Price to Median PS Value of Assertio Holdings was 1.20. The lowest was 0.13. And the median was 0.43.
ASRT's Price-to-Median-PS-Value is ranked better than 89.42% of 501
companies
in the Drug Manufacturers industry
Industry Median: 0.85
vs ASRT: 0.37
Assertio Holdings Median PS Value Historical Data
The historical data trend for Assertio Holdings's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Assertio Holdings's Median PS Value
For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assertio Holdings's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Assertio Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.1318.
Assertio Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.2.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assertio Holdings (NAS:ASRT) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Assertio Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.914
/
2.49
=
0.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assertio Holdings Median PS Value Related Terms
Thank you for viewing the detailed overview of Assertio Holdings's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Assertio Holdings (Assertio Holdings) Business Description
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASRT has been successfully added to your 